APPENDICURE

A New Study and the Clinical Trials Patients Should Know About

Immunotherapy has transformed the treatment of several cancers, particularly blood cancers such as leukemia and lymphoma. One of the most promising approaches is CAR-T cell therapy, a treatment that re-engineers a patient’s own immune cells to recognize and attack cancer.

However, CAR-T therapy has historically been much more difficult to use in solid tumors, including gastrointestinal cancers.

A newly published early-stage study suggests researchers may be starting to overcome some of those barriers. You can see the original article here.

While this research is still in its early stages, it represents an important development that appendix cancer patients and caregivers may want to be aware of and discuss with their medical teams.

A New CAR-T Study Targeting CEA-Positive Tumors

Researchers recently published results from a Phase 1 clinical trial evaluating a CAR-T therapy called PC13. The therapy targets carcinoembryonic antigen (CEA), a protein frequently found on the surface of many gastrointestinal cancers.

CEA is particularly relevant because:

• Many appendiceal adenocarcinomas express CEA
• CEA is already used clinically as a tumor marker to monitor some gastrointestinal cancers

The study enrolled 43 patients with advanced CEA-positive solid tumors who had already received multiple prior treatments.

Participants received the CAR-T therapy using two different approaches:

• Intravenous (IV) infusion
• Intraperitoneal (IP) infusion, meaning the therapy was delivered directly into the abdominal cavity

The intraperitoneal approach is especially interesting for appendiceal cancer patients.

Why Intraperitoneal Treatment Matters

Unlike many cancers that spread through the bloodstream, appendiceal cancer often spreads within the abdominal cavity, a process known as peritoneal metastasis.

This is the same reason treatments such as HIPEC (hyperthermic intraperitoneal chemotherapy) are delivered directly into the abdomen.

In this study:

• The disease control rate reached 82% in patients receiving intraperitoneal treatment.
• The objective response rate was 23.5%.

Among a small subgroup of patients with:

• Peritoneal metastases
• Very high CEA expression

Researchers observed response rates as high as 57%.

Because this was a Phase 1 trial, its primary goal was to evaluate safety rather than effectiveness. Larger studies will be needed to confirm these results.

However, the findings suggest that CEA-targeted CAR-T therapy delivered directly into the abdominal cavity may deserve further study for cancers that spread along the peritoneum.

How CAR-T Cell Therapy Works

Why CAR-T Therapy Has Been Difficult for Solid Tumors

CAR-T therapy has produced remarkable results in some blood cancers. But solid tumors present several challenges.

Tumors can:

• create low-oxygen environments (tumor hypoxia)
• produce immune-suppressing signals
• form physical barriers that prevent immune cells from entering

The therapy studied in this trial was designed to address one of these issues.

The CAR-T cells are hypoxia-responsive, meaning they activate more effectively in low-oxygen tumor environments.

This type of innovation is part of a broader effort to adapt CAR-T therapy for solid tumors and peritoneal cancers.

Other CAR-T Strategies Being Studied for Peritoneal Cancers

Researchers around the world are exploring multiple CAR-T approaches that could potentially apply to cancers that spread in the abdominal cavity.

CEA-Targeted CAR-T Cells

CEA is commonly found in gastrointestinal tumors. Several clinical trials are studying CAR-T therapies designed to recognize this protein.

Some studies are testing regional delivery directly into the peritoneal cavity, which may improve the ability of CAR-T cells to reach tumors.

Mesothelin-Targeted CAR-T Cells

Another important target is mesothelin, a protein frequently found in cancers that spread along the abdominal lining.

Mesothelin is expressed in several cancers including:

• mesothelioma
• pancreatic cancer
• ovarian cancer
• some appendiceal tumors

Because mesothelin has limited expression in normal tissues, it has become a promising target for next-generation CAR-T therapies.

Next-Generation “Armored” CAR-T Cells

Researchers are also developing CAR-T cells specifically designed for the challenges of solid tumors.

These include:

• Hypoxia-activated CAR-T cells
• “Armored” CAR-T cells that release immune-stimulating molecules
• Multi-target CAR-T cells that recognize multiple tumor markers

These strategies aim to help immune cells survive and function within the complex tumor environment.

Clinical Trials Appendix Cancer Patients May Want to Watch

Because appendix cancer is rare, many trials do not list it specifically. Instead, patients may qualify under broader categories such as:

• CEA-positive solid tumors
• gastrointestinal cancers
• peritoneal metastases

Examples of trials exploring these therapies include:

CEA-Targeted CAR-T Trials

NCT05396300 – Completed
Hypoxia-responsive CEA CAR-T therapy (PC13)

NCT02349724
CEA-directed CAR-T cells for gastrointestinal cancers

Mesothelin CAR-T Trials

NCT02414269
Regional mesothelin CAR-T therapy

Clinical trial eligibility varies widely, and patients should discuss trial options with their medical teams.

How CAR-T Cell Therapy Works

New immunotherapy approaches for cancers that spread in the abdominal cavity

Where This Research Is Happening

Many CAR-T studies for gastrointestinal and peritoneal cancers are taking place at leading research centers.

Institutions currently involved in CAR-T or engineered T-cell therapy trials include:

MD Anderson Cancer Center
Houston, Texas

City of Hope National Medical Center
California

National Cancer Institute (NIH)
Bethesda, Maryland

Memorial Sloan Kettering Cancer Center
New York

University of Pennsylvania
Philadelphia

Fred Hutchinson Cancer Center
Seattle

These centers are among the global leaders in cell therapy research and early-phase clinical trials.

Patients interested in emerging therapies sometimes seek second opinions at these or similar academic cancer centers.

What This Means for Appendix Cancer Patients

CAR-T therapy is not currently an approved treatment for appendiceal cancer.

However, this research is significant for several reasons.

First, it shows that scientists are developing CAR-T therapies specifically designed for solid tumors and peritoneal cancers.

Second, the targets being studied — particularly CEA and mesothelin — may be present in some appendiceal tumors.

Third, researchers are exploring intraperitoneal delivery, which directly targets the area where appendix cancer commonly spreads.

Finally, these studies highlight the growing importance of tumor biomarker testing, which may help determine eligibility for certain clinical trials.

Questions Appendix Cancer Patients May Want to Ask Their Doctor

Patients interested in emerging immunotherapy approaches may wish to discuss questions like these with their care team.

About Tumor Biology

• Has my tumor been tested for CEA expression?
• Does my cancer express mesothelin or other potential immunotherapy targets?

About Clinical Trials

• Are there clinical trials studying CEA-targeted therapies that may apply to my cancer?
• Are there trials involving intraperitoneal immunotherapy?

About Eligibility

• Would my treatment history allow me to participate in early-phase clinical trials?

About Next Steps

• Should we consider additional biomarker testing to identify trial opportunities?
• Would a second opinion at a rare cancer center be helpful?

Key Takeaways for Appendix Cancer Patients

CAR-T therapy is an experimental immunotherapy being studied for solid tumors.

A recent study targeting CEA-positive cancers showed encouraging early signals in patients with peritoneal metastases.

Some appendiceal tumors express CEA or mesothelin, which are targets under investigation.

Researchers are exploring intraperitoneal delivery, which may be relevant for cancers that spread in the abdomen.

Several clinical trials may potentially include CEA-positive gastrointestinal cancers.

Why It’s Important to Share Research With Your Medical Team

Cancer research is advancing rapidly.

Even physicians who specialize in rare cancers cannot track every new study, therapy, or clinical trial being developed around the world.

Patients and caregivers sometimes play an important role in helping bring emerging research into the conversation.

Sharing information with your medical team is not questioning their expertise. It is simply part of working together to explore every possible option.

If you come across research like the study discussed here, consider asking your doctor whether it may be relevant to your situation.

The Bottom Line

CAR-T therapy is still in the early stages of development for solid tumors, including appendiceal cancer.

However, new strategies targeting CEA, mesothelin, and peritoneal disease are beginning to show encouraging signals.

While these therapies are not yet standard treatment options, they represent a growing area of research that may eventually expand options for patients with advanced disease.

Staying informed and maintaining open conversations with your care team can help ensure that promising new ideas are considered whenever appropriate.